Northland Capmk Forecasts Higher Earnings for MiMedx Group

MiMedx Group, Inc. (NASDAQ:MDXG) – Analysts at Northland Capmk increased their Q1 2025 earnings estimates for shares of MiMedx Group in a research report issued to clients and investors on Thursday, February 27th. Northland Capmk analyst C. Byrnes now anticipates that the company will earn $0.06 per share for the quarter, up from their previous forecast of $0.05. The consensus estimate for MiMedx Group’s current full-year earnings is $0.30 per share. Northland Capmk also issued estimates for MiMedx Group’s Q2 2025 earnings at $0.07 EPS, Q3 2025 earnings at $0.07 EPS, Q4 2025 earnings at $0.08 EPS and FY2026 earnings at $0.38 EPS.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, hitting the consensus estimate of $0.07. The company had revenue of $92.91 million during the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%.

Other equities research analysts have also recently issued reports about the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 target price on shares of MiMedx Group in a research report on Thursday. StockNews.com downgraded shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $12.40.

MiMedx Group Trading Up 3.2 %

Shares of MDXG stock opened at $8.40 on Friday. MiMedx Group has a fifty-two week low of $5.47 and a fifty-two week high of $10.14. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The stock’s fifty day moving average is $8.72 and its two-hundred day moving average is $7.70. The firm has a market capitalization of $1.23 billion, a P/E ratio of 15.27 and a beta of 1.94.

Hedge Funds Weigh In On MiMedx Group

Several institutional investors and hedge funds have recently bought and sold shares of the company. Jane Street Group LLC increased its position in shares of MiMedx Group by 133.6% during the third quarter. Jane Street Group LLC now owns 305,652 shares of the company’s stock valued at $1,806,000 after acquiring an additional 174,797 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of MiMedx Group by 265.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company’s stock worth $1,757,000 after purchasing an additional 215,995 shares during the period. Barclays PLC boosted its position in shares of MiMedx Group by 163.9% during the 3rd quarter. Barclays PLC now owns 262,449 shares of the company’s stock worth $1,550,000 after purchasing an additional 163,005 shares during the period. Farther Finance Advisors LLC raised its position in MiMedx Group by 88.6% in the third quarter. Farther Finance Advisors LLC now owns 24,599 shares of the company’s stock valued at $145,000 after purchasing an additional 11,557 shares during the period. Finally, Harbor Capital Advisors Inc. raised its position in MiMedx Group by 299.9% in the third quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock valued at $6,074,000 after purchasing an additional 770,744 shares during the period. 79.15% of the stock is currently owned by institutional investors and hedge funds.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.